Clinical trials: Mesenchymal Tumor
Sarcoma
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002995
- Testing
- dactinomycin, filgrastim, sargramostim
- Where
- 233 sites in United States, Australia and 5 more
- Volunteers
- 483 people
- Sponsor
- Children's Oncology Group
Children, Solid Tumors
Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors.
The investigators will evaluate the safety of weekly infusions (n=6) of CELYVIR in children and adults with metastatic and refractory solid tumors.
- Conditions
- Children, Solid Tumors, Metastases
- Trial name
- NCT01844661
- Testing
- CELYVIR
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Leukemia, Multiple Myeloma
MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis
Evaluating the effectiveness of the new protocol which replace the standard immunosuppressive therapy with use of MSCs and CY in patients at high risk of relapse.
- Trial name
- MSC-CY (NCT02270307)
- Testing
- Cyclophosphamide, Mesenchymal stromal cells
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- National Research Center for Hematology, Russia
Sarcoma
Tissue Sample Collection From Patients With Soft Tissue Sarcoma of the Arms, Hands, Legs, or Feet Treated on Clinial Trial CRUK-VORTEX
RATIONALE: Collecting and storing samples of tumor tissue from patients with soft tissue sarcoma to test in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00900211
- Testing
- microarray analysis, molecular diagnostic method, biologic sample preservation procedure
- Where
- 12 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- The Christie NHS Foundation Trust
Solid Tumor, Metastatic Cancer
Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy
This is a Phase 1 clinical study to investigate the safety, pharmacokinetics and pharmacodynamics of AB-16B5 in patients with an advanced solid malignancy.
- Trial name
- NCT02412462
- Testing
- AB-16B5
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Alethia Biotherapeutics
Erectile Dysfunction, Prostate Cancer
Stem Cells for Erectile Dysfunction Post RALP
This is a phase 1/2 single center, pilot study to assess safety and efficacy of allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) and to evaluate the timing and combination effects of active treatment versus placebo…
- Trial name
- NCT07048314
- Testing
- Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office, Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The Methodist Hospital Research Institute
Clear Cell Chondrosarcoma, Dedifferentiated Chondrosarcoma
Vismodegib in Treating Patients With Advanced Chondrosarcomas
This phase II trial studies how well vismodegib works in treating patients with chondrosarcomas that have spread to other places in the body and usually cannot be cured or controlled with treatment.
- Conditions
- Clear Cell Chondrosarcoma, Dedifferentiated Chondrosarcoma, Locally Advanced Chondrosarcoma, Mesenchymal Chondrosarcoma
- Trial name
- NCT01267955
- Testing
- Laboratory Biomarker Analysis, Pharmacogenomic Study, Vismodegib
- Where
- 6 sites in France
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating…
- Conditions
- Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma
- Trial name
- NCT01154452
- Testing
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Bone Cyst
Treatment Of Bone Cyst With Bone Marrow Mesenchymal Cell Transplantation
There are two types of bone cysts, unicameral and aneurismal. These cysts happen to anyone, but they are most commonly seen in children and young adults while their bones are still growing.
- Trial name
- NCT01207193
- Testing
- cell injection
- Where
- Iran
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Royan Institute
Sarcoma
Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00379457
- Testing
- dactinomycin, carboplatin, cyclophosphamide
- Where
- 27 sites in Austria, Belgium and 6 more
- Volunteers
- 600 people
- Sponsor
- European Paediatric Soft Tissue Sarcoma Study Group
Pediatric Cancer, Chronic Sinusitis
Post-radiotherapy Rhinosinusitis in Children
Chronic rhinosinusitis (CRS) is a frequent complication of facial cancer treatment, mainly related to radiotherapy. However, while radiological involvement is frequent, clinical expression seems less important.
- Trial name
- PRRSC (NCT05454163)
- Testing
- SNOT 22 questionnaire
- Sponsor
- University Hospital, Lille
Colonic Neoplasms
Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy
In this proof-of-concept trial the investigators will study the effects of imatinib treatment on the biology of mesenchymal-type colon cancers.
- Trial name
- ImPACCT (NCT02685046)
- Testing
- Imatinib
- Where
- 3 sites in Netherlands
- Volunteers
- 5 people
- Sponsor
- UMC Utrecht
NSCLC
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093.
- Trial name
- NCT04077099
- Testing
- REGN5093
- Where
- 29 sites in United States, France and 1 more
- Volunteers
- 95 people
- Sponsor
- Regeneron Pharmaceuticals
Prostate Cancer
Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer
The objective of this study is to determine if systemically infused allogeneic bone marrow derived mesenchymal stem cells (MSC) home to sites of prostate cancer in men with localized adenocarcinoma of the prostate that are…
- Trial name
- MSC (NCT01983709)
- Testing
- Allogeneic Human Mesenchymal Stem Cells
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer
"High Levels of EMT-TFs for the Diagnosis of Colorectal Cancer (CRC)"
The present study is aimed at detecting and measuring mRNA levels of genes involved in epithelial to mesenchymal transition (EMT) in biological samples, i.e.
- Trial name
- NCT04323813
- Testing
- Liquid biopsy
- Where
- Italy
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Istituto Clinico Humanitas
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Xerostomia Following Radiotherapy
Safety and Efficacy of Mesenchymal Stem Cell for Radiation-induced Hyposalivation and Xerostomia in Previous Head and Neck Cancer Patients
The incidence of head and neck cancer is increasing in the Western World, including Denmark. Cancer of the head and neck and its treatment often have a detrimental and lifelong impact on the quality of life of the patients.
- Trial name
- MESRIX-III (NCT04776538)
- Testing
- Stem cells
- Where
- Denmark
- Volunteers
- 120 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Metastatic Triple-Negative Breast Carcinoma
The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC
Triple-negative breast cancer (TNBC) is biologically aggressive and has limited systemic treatment options, often compounded by treatment resistance. Cell state transitions, e.g.
- Trial name
- NCT04664829
- Testing
- Bexarotene, Capecitabine
- Where
- Singapore
- Volunteers
- 12 people
- Sponsor
- National Cancer Centre, Singapore
KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation that has spread to…
- Conditions
- KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT03608631
- Testing
- Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Malignancies
Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease
MESENCHYMAL STROMAL CELLS (MSC) have shown promising albeit not always consistent therapeutic effects in the treatment of severe steroid-resistant acute Graf versus Host Disease.
- Trial name
- PTC-UC-MSC (NCT02032446)
- Testing
- UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)
- Where
- 8 sites in Italy
- Volunteers
- 47 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII